Ceapro (TSXV:CZO) Debt-to-Equity : 0.08 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Ceapro Debt-to-Equity?

Ceapro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.40 Mil. Ceapro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$1.85 Mil. Ceapro's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$27.86 Mil. Ceapro's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ceapro's Debt-to-Equity or its related term are showing as below:

TSXV:CZO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.1 Max: 1.66
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of Ceapro was 1.66. The lowest was 0.03. And the median was 0.10.

TSXV:CZO's Debt-to-Equity is ranked better than
64.13% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSXV:CZO: 0.08

Ceapro Debt-to-Equity Historical Data

The historical data trend for Ceapro's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Debt-to-Equity Chart

Ceapro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.15

0.12

0.10

0.08

Ceapro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.08	0.08	0.08	0.08

Competitive Comparison of Ceapro's Debt-to-Equity

For the Biotechnology subindustry, Ceapro's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceapro's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceapro's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ceapro's Debt-to-Equity falls into.

Ceapro Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ceapro's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.396	+	1.852)	/	27.855
	=	0.08

Ceapro's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.396	+	1.852)	/	27.855
	=	0.08

Ceapro (TSXV:CZO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ceapro Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ceapro's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ceapro (TSXV:CZO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CRPOF:USA

Address

7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2

Website

https://www.ceapro.com

Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines